Your greatest defense is within you. Immunocine was founded to bring revolutionary immunotherapy to cancer patients who are not eligible for FDA clinical trials. Our proprietary treatment, Immunocine Dendritic Cell Therapy (IDCT), “double loads” a patient’s dendritic cells with their own cancer cells. This process mimics a viral infection and triggers a powerful, targeted immune response. Backed by 16 years of research and ongoing FDA trials, IDCT offers a less invasive, highly precise option for treating multiple types of cancer. Visit our website to see if you’re eligible to apply for treatment.
Shared 1 month ago
234 views
Shared 1 month ago
711 views
Shared 3 months ago
213 views
Shared 5 months ago
1.1K views
Shared 6 months ago
5.8K views
Shared 7 months ago
400 views
Shared 8 months ago
569 views
Shared 8 months ago
549 views
Shared 9 months ago
968 views
Shared 11 months ago
1.1K views
Shared 11 months ago
1K views
Shared 1 year ago
3.6K views
Shared 1 year ago
2K views
Shared 1 year ago
721 views
Shared 1 year ago
1.6K views
Shared 1 year ago
331 views
Shared 1 year ago
386 views
Shared 1 year ago
649 views
Shared 1 year ago
6.6K views
Shared 1 year ago
3.1K views
Shared 1 year ago
890 views
Shared 1 year ago
4K views
Shared 2 years ago
3.2K views
Shared 2 years ago
2.3K views
Shared 2 years ago
1.6K views
Shared 3 years ago
4K views
Shared 3 years ago
465 views
Shared 3 years ago
687 views
Shared 3 years ago
2.3K views